TNBC, TRIPLE NEGATIVE BREAST CANCER

This study tests a new immunotherapy drug (QL1706) combined with short cycles of chemotherapy for people with early-stage triple-negative breast cancer (TNBC), an aggressive type. About 30 participants will receive either QL1706 plus one chemo pair or another, to see if the combi…

This early-phase study tests a new drug, BG-68501, in people with advanced solid tumors (like breast, ovarian, lung, or stomach cancer) that have not responded to standard treatments. The goal is to find a safe dose and see if the drug shrinks tumors when used alone or with other…

This study tests whether adding the immunotherapy drug pembrolizumab, with or without the targeted drug olaparib, to standard radiation therapy is safe and effective for people with metastatic triple-negative or hormone-receptor-positive/HER2-negative breast cancer. About 34 part…

This program offers investigational leronlimab to adults with advanced triple-negative breast cancer who have run out of standard treatments. Participants must have stage IIIB-IV disease and cannot join a clinical trial. The goal is to provide a potential treatment option when no…

This study tests whether an MRI scan after the first part of chemotherapy can identify women with triple-negative breast cancer who have responded so well that they can skip the second, more toxic part of treatment. About 54 participants will receive 12 weeks of chemo plus immuno…

This early-stage study tests a new drug called BAL0891, given alone or with chemotherapy or immunotherapy, in people with advanced solid tumors or relapsed acute myeloid leukemia (AML). The main goals are to check safety and find the best dose. About 260 adults will take part acr…

This study tests if injecting the drug INT230-6 into breast tumors before standard chemotherapy and immunotherapy can help eliminate all cancer in the breast and lymph nodes. About 61 people with early triple-negative breast cancer (a fast-growing type) will be randomly assigned …

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can help eliminate triple-negative breast cancer in 35 women. Participants will receive the combination treatment, then have surgery to check if no cancer remains. The goal …

This study tests whether adding a drug called axatilimab (which targets immune-suppressing cells) and radiation to standard immunotherapy (pembrolizumab) can help eliminate high-risk triple-negative breast cancer before surgery. About 35 women with low immune activity in their tu…

This early-phase study tests a new drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to seek out and destroy cancer cells. The study will check for safety and side effect…

This early-stage trial tests adding dupilumab (a drug for allergies and asthma) to standard chemotherapy and immunotherapy for people with locally advanced triple-negative breast cancer. The main goal is to see if the combination is safe and does not cause severe immune-related s…

This study tests whether adding the drug ivonescimab to standard chemotherapy before surgery can improve outcomes for people with early-stage triple-negative breast cancer. About 34 participants will receive the combination every three weeks for six cycles, then undergo surgery t…

This early-phase study tests a new drug called 177Lu-RAD204, which combines a targeting antibody with a radioactive particle to seek out and attack cancer cells. The trial involves 30 adults with advanced solid tumors like lung, breast, or skin cancer that have not responded to o…

This study tests a three-drug combination (alpelisib, L-NMMA, and chemotherapy) in people with a rare, aggressive type of breast cancer called metaplastic breast cancer that has spread or is locally advanced and hasn't responded to prior treatments. The goal is to see if adding t…

This study tests whether adding two drugs (sintilimab and bevacizumab) to standard chemotherapy before surgery can eliminate all signs of triple-negative breast cancer in 37 women. The main goal is to see how many patients have no cancer left in the removed tissue. This approach …

This study is for people with triple-negative breast cancer whose tumors did not shrink after standard chemotherapy. The goal is to see if adding a short course of high-precision radiation followed by an immunotherapy drug (toripalimab) and more chemo can make the cancer disappea…

This early-phase trial tests a new drug, TUB-030, in adults with advanced solid tumors like head and neck, lung, breast, or colorectal cancer. The main goals are to find a safe dose and check for side effects. Researchers will also compare different doses in people with head and …

This study tests a new oral drug, AVZO-021, in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein called CDK2 to slow or stop cancer growth. The trial has two phases: first to find the safest dose, then to see if it shrinks t…

This study tests whether adding targeted radiation (SBRT) to standard chemotherapy and immunotherapy can improve outcomes for people with early-stage triple-negative breast cancer (TNBC). TNBC is a hard-to-treat type of breast cancer with fewer treatment options. The trial will e…

This study tests a new imaging system that uses light to monitor how well breast cancer responds to chemotherapy before surgery. Researchers want to see if it can accurately predict when the cancer is completely gone, which could help some patients avoid additional treatments. Th…

This study compares a contrast-enhanced digital mammogram (CEDM+CEDBT) with standard breast MRI to see if it can accurately predict whether breast cancer has been eliminated by chemotherapy before surgery. About 30 women with locally advanced breast cancer will get 1-2 of these s…

This study follows 300 Chinese women with metastatic triple-negative breast cancer to see how their quality of life changes during treatment. Participants receive either sacituzumab govitecan or standard chemotherapy chosen by their doctor. The goal is to understand how these tre…

This study collects tumor samples from 2,000 people with various cancers to learn how to predict who will respond to immunotherapy. Participants donate tissue during a routine biopsy. The goal is to understand tumor biology and improve future treatment decisions, not to test a ne…

This study is testing whether adding new experimental drugs to standard chemotherapy before surgery can improve outcomes for people with breast cancer. It includes up to 5,000 participants with early-stage or locally advanced breast cancer. The goal is to use MRI scans and tissue…

This study looks at whether changes in a simple blood marker called CRP can help predict how well immunotherapy works in people with triple-negative breast cancer. Researchers will follow 225 women with early or advanced disease who are receiving standard immunotherapy. The goal …

This study looks at whether a simple blood test can find tiny bits of cancer DNA left in the body after breast cancer treatment. Finding this DNA, called minimal residual disease, may help predict if the cancer will come back. The study will follow 900 people with different types…